The global antibody drug conjugates market was valued at USD 11.29 billion in 2023. It is expected to grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2030. This growth is driven by a strong R&D pipeline. There is also a rising incidence of cancer. The demand for low-toxicity and effective drugs supports market expansion.
Key antibody drug conjugates (ADCs) currently available include Kadcyla, Adcetris, Enhertu, Besponsa, Mylotarg, and Polivy. ADCs are a novel class of drugs. They consist of an antibody linked to a cytotoxic drug via a chemical linker.
Conventional chemotherapy targets fast-growing tumor cells. However, it can also harm healthy cells. ADCs aim to enhance treatment efficacy while reducing systemic toxicity. In developed economies, reimbursement policies significantly influence this market. ADCs are more expensive to produce than conventional treatments. This results in higher overall treatment costs. Such costs can challenge reimbursement coverage. For example, Roche's Kadcyla received a negative review in Ireland in February 2020.
Gather more insights about the market drivers, restrains and growth of the Antibody Drug Conjugates Market
Product Segmentation Insights
In 2023, Kadcyla generated the largest revenue in the ADC market. The rise in breast cancer cases fuels demand for ADCs designed for this type of cancer. In January 2022, Roche received approval for Kadcyla in China, marking a significant milestone.
In 2023, Roche made a strategic move to lower Kadcyla's price by over 50% in China. This adjustment aimed to capture a larger market share. China has become Roche's second-largest market, up from tenth. This price reduction reflects Roche's evolving strategy in the Chinese market.
Enhertu is one of the fastest-growing segments in the ADC market. DAIICHI SANKYO COMPANY and AstraZeneca's Enhertu has seen rising sales projections. Its groundbreaking approval for HER2-low breast cancer in August 2022 marked an industry-first achievement. Daiichi highlighted Enhertu's rapid adoption for this new indication. This new indication serves patients previously classified as HER2-negative. Since its launch for second-line HER2-positive breast cancer in May 2022, Enhertu has outperformed competitors. It has secured the largest share of new patients in this category.
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
